The United States alone spends over $30 billion each year on child and adolescent mental health services. The UK’s NHS spends roughly £1.5 billion. Across the OECD, the figure is in the hundreds of billions, and it has climbed sharply since the pandemic. Yet for all that money, we have almost no idea whether these services make a lasting difference in children’s lives.
Most services track how many sessions they deliver, how long families wait, and whether patients are satisfied. Very few track what happens to children after treatment ends—whether they do better in school, stay out of crisis, or go on to lead mentally healthy adult lives. The gap between what we spend and what we measure is not a minor bureaucratic oversight; it’s a fundamental failure to know whether one of the largest public investments in child wellbeing actually works.
A $30 Billion Question Mark
When a child receives mental health treatment, the funders—governments, insurers, schools—usually want to know three things: How many sessions were provided? Did the family show up? Were they satisfied? These are questions about inputs and process, not outcomes.
Routine outcome monitoring, the systematic tracking of a child’s functioning and symptoms over time, is rare. Studies suggest fewer than 10–20% of services consistently measure outcomes beyond discharge. And even when they do, follow-up typically stops at six months. Virtually no routine data follows children into adulthood.
This means that for a condition like adolescent depression—which is linked to lifelong disability, poor educational attainment, and increased suicide risk—we are spending billions without knowing if treatment alters that trajectory.
Short-Term Wins, Long-Term Unknowns
It’s not that child mental health treatments are ineffective. In randomized controlled trials, therapies like cognitive-behavioral therapy (CBT), family therapy, and parenting programs show moderate to large effects for anxiety, depression, and conduct disorder—Cohen’s d values typically between 0.3 and 0.8. That’s meaningful improvement.
But trials are not real life. In community settings, dropout rates run between 30% and 50%, and effectiveness often lags behind efficacy. More troubling, few studies follow treated children beyond two to five years. The ones that do produce mixed results: some children sustain gains, others relapse, and some end up no better than untreated peers. Because many children with mental health difficulties improve naturally without any intervention, it’s hard to attribute long-term change to the service—or the lack of it.
Why We’re Flying Blind
The reasons for this measurement gap are not technical. We have the tools to track outcomes. The barriers are structural and cultural.
First, funding structures pay for episodes of care, not outcomes. There’s no financial incentive to know if a treatment worked months later. Second, tracking children for years is expensive, requires ongoing consent, and raises privacy concerns. Third, services are fragmented: children move between schools, GPs, specialist clinics, and adult services, and no single agency owns the data across that journey.
Finally, many clinicians resist outcome measurement, seeing it as bureaucratic interference rather than clinical tool. Some worry that outcome-based accountability would lead to gaming—cherry-picking easy cases—or risk-averse practice that avoids complex patients. Others, though, welcome better data, arguing it would sharpen clinical judgment and justify scarce resources.
Policy Promises, Slow Progress
Policymakers have made some gestures toward better measurement. In the UK, the NHS Long Term Plan promised more outcome tracking, and the CYP IAPT program introduced session-by-session measures. But data quality is patchy and follow-up remains poor. Australia’s Better Access scheme funds sessions without mandating outcome tracking. Even in Norway, which has some of the best routine data through its BUP system, long-term follow-up is rare.
In the US, Medicaid requires some quality reporting, but it’s mostly process measures. The Center for Medicare and Medicaid Innovation has piloted outcome-based payment models, but uptake has been limited. The result: we continue to spend vast sums on a system we cannot fully evaluate.
The Cost of Ignorance
The economic angle is stark. When cost-effectiveness analyses are done for child mental health interventions, the results are often disappointing—some parenting programs, for example, show poor cost-effectiveness at scale. And every pound or dollar spent on ineffective services is money not spent on prevention, schools, or social care—areas that might yield better long-term returns.
For families, the stakes are personal. They report long waits, short sessions, and poor communication, yet they are often deeply grateful for any help their child receives. But they are rarely asked about long-term outcomes. The system treats a child as ‘treated’ at discharge, regardless of what happens next.
A Way Forward?
Closing the measurement gap won’t be easy, but it’s not impossible. What’s needed is a shift from volume-based to value-based care, where services are held accountable for outcomes that matter—functioning, school attainment, adult mental health—not just session counts.
This requires investment in long-term data infrastructure, linking health records with education and social care data. It requires outcome measurement to be embedded in routine practice, not bolted on as an afterthought. And it requires a cultural change among clinicians, funders, and policymakers to see outcome data as essential to good care, not a threat.
The pandemic has made this more urgent. Youth mental health need has surged, and spending has followed. If we don’t know what works, we risk pouring billions more into a system that may be failing the very children it claims to help.
We spend billions on child mental health services, but we are flying blind on whether they deliver lasting benefits. Short-term gains are real, but long-term outcomes remain largely unmeasured. It’s time to ask not just ‘Did the child show up?’ but ‘Did the child get better—and did that improvement last?’
Summary
- The US spends over $30 billion annually, and the UK £1.5 billion, on child mental health services, yet fewer than 10–20% of services track outcomes beyond discharge.
- Evidence-based therapies work in trials (moderate effect sizes), but real-world effectiveness is lower, and long-term follow-up is rare.
- Structural barriers—funding per episode, fragmented systems, privacy concerns—explain the measurement gap, not lack of tools.
- Policy efforts like the UK’s CYP IAPT and Norway’s BUP have improved data, but long-term tracking remains inadequate.
- Moving to value-based care, with outcome-linked payments and long-term data infrastructure, is essential to know if interventions truly work.
FAQ
Q: How much does the US spend on child mental health services?
A: The US spends over $30 billion annually, including Medicaid, CHIP, private insurance, and school-based programs.
Q: Why is it so hard to measure long-term outcomes in child mental health?
A: Barriers include fragmented service systems, lack of financial incentives, privacy concerns, and the high cost of long-term tracking. Many clinicians also resist outcome measurement as bureaucratic.
Q: Do child mental health treatments work in the long term?
A: Evidence is mixed. Some children sustain gains, but others relapse or show no difference from untreated peers. Natural recovery is also common, making it hard to attribute improvements to treatment.
Q: What is routine outcome monitoring (ROM)?
A: ROM is the systematic tracking of a child’s functioning and symptoms over time. It’s rare in child services; fewer than 10–20% of services use it beyond discharge.
Q: What would improve the situation?
A: A shift to value-based care, with payments tied to outcomes, plus investment in long-term data infrastructure and embedding outcome measurement in routine practice.